Treatment of drug resistant cancer
The present invention discloses novel agents and methods for diagnosis and treatment of melanoma. Also disclosed are related arrays, kits, and screening methods.
1. A method of treating drug resistant cancer in a subject in need thereof, comprising administering to the subject an effective amount of an LXRβ agonist, or a pharmaceutically acceptable salt thereof, and a PD-1 inhibitor or PD-L1 inhibitor, wherein said inhibitor is nivolumab or atezolizumab (MPDL3280A), wherein said drug resistant cancer is breast cancer, non-small cell lung cancer, or ovarian cancer, and wherein said LXRβ agonist is:
2. The method of claim 1 , wherein said drug resistant cancer is metastatic.
3. The method of claim 1 , comprising administration of an additional anticancer therapy.
4. The method of claim 3 , wherein said additional anticancer therapy is an antiproliferative.
5. The method of claim 4 , wherein said antiproliferative is a VEGF inhibitor, a VEGFR2 inhibitor, and/or a CTLA4 inhibitor.
6. The method of claim 3 , wherein said antiproliferative is ipilmumab or vemurafenib.
7. The method of claim 1 , wherein said LXRβ agonist is administered in an amount sufficient to slow the spread of said drug resistant cancer.
8. The method of claim 2 , wherein said LXRβ agonist is administered in an amount sufficient to increase the expression level or activity level of ApoE to a level sufficient to slow the spread of metastasis of said drug resistant cancer.
9. The method of claim 1 , wherein said drug resistant cancer is ovarian cancer.
10. The method of claim 9 , wherein said ovarian cancer is resistant to platinum agents.
11. The method of claim 1 , wherein said drug resistant cancer is breast cancer.
12. The method of claim 11 , wherein said breast cancer is triple negative breast cancer.
13. The method of claim 1 , wherein said drug resistant cancer is non-small cell lung cancer.
14. The method of claim 1 , wherein the subject is administered an effective amount of an LXRβ agonist, or a pharmaceutically acceptable salt thereof, and a PD-1 inhibitor, wherein the PD-1 inhibitor is nivolumab.
15. The method of claim 1 , wherein the subject is administered an effective amount of an LXRβ agonist, or a pharmaceutically acceptable salt thereof, and a PD-L1 inhibitor, wherein the PD-L1 inhibitor is atezolizumab (MPDL3280A).